ZEDRA
19.7.2022 10:02:06 CEST | Business Wire | Press release
ZEDRA, the fast-growing international specialist in Active Wealth, Corporate & Global Expansion, and Fund solutions, today announces that the firm is launching a new pensions-focused offering – Pensions & Incentives.
The launch follows several recent acquisitions in the UK pension services space by ZEDRA, including Inside Pensions, a leading independent occupational pension scheme governance support provider PTL, a leading independent Pension Trustee and Governance services provider, both in 2021; and most recently, Caledonian Trustees Limited, a specialist provider of professional independent trustee and secretarial services to corporate pension and funeral plans. As the new offering goes live, PTL Limited has adopted the ZEDRA brand and become ZEDRA Governance Limited.
ZEDRA launches this offering as the UK pension trustee and governance services sector is undergoing significant changes and facing challenges that will require both dedicated effort and investment from long-term owners. As the regulatory system has become increasingly complex over recent years, so has the challenge of running a pension scheme for employers and trustees alike.
The number of pension schemes requiring support is expected to continue to grow for the foreseeable future, due to significantly increased regulatory and compliance burdens, a focus on end game strategies which benefit from professional trustee knowledge and understanding, and a lack of available company or member nominated trustees. With its new Pensions & Incentives offering, ZEDRA is expanding its services to meet these needs.
By entering the pension services industry now, ZEDRA strengthens its 20 years of presence in the employee incentive solutions and pension services space, providing global clients with employee benefits, trustee services, pensions and associated administrative solutions, through a dedicated team in Guernsey. Trustee services have always been at the heart of ZEDRA – the firm was founded in 2016 following the sale by Barclays of its -UK and offshore trust business to a group of private investors, including ZEDRA’s current Executive Chairman, Bart Deconinck.
ZEDRA Pensions & Incentives Services will consist of six offices in London, Reading, Leeds, Birmingham, St Albans and Guernsey and is made up of approximately 80 specialists with plans to further expand the team with acquisitions in the near future in the UK and Europe.
Ivo Hemelraad, ZEDRA Chief Executive Officer , said: “We are delighted to further expand our service offering by boosting our presence in the UK pension space. The journey we started with the acquisition of Interben Trustees Limited in 2019 followed by Inside Pensions, PTL and more recently, Caledonian Trustees, brings us to a market leading position for outsourced pension services in the UK pension space and abroad. Our dedicated teams with unrivalled expertise allow us to offer even greater service to those who are committed to providing the highest quality pension schemes available.”
ENDS
Notes to Editors
For more information, please contact:
Greentarget
Jamie Brownlee / Tom Engleback / Eleonore Basle / Sebastian Merrett
+44 203 963 1893
zedra@greentarget.co.uk
About ZEDRA
Find out more at www.zedra.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
